Study Compares Tirzepatide and Semaglutide for Weight Loss
A new large-scale study indicates that tirzepatide leads to more significant weight loss than semaglutide. Tirzepatide acts on two gut hormones, while semaglutide acts on only one.
A recent 16-month study has compared two leading medical weight loss medications: tirzepatide and semaglutide. The research, which analyzed data from approximately 18,000 overweight or obese adults, suggests that tirzepatide is more effective in driving weight reduction.
According to the findings, patients treated with tirzepatide achieved considerably greater weight loss on average compared to those taking semaglutide. For instance, at the 12-month mark, individuals on tirzepatide were three times more likely to have lost at least 15% of their body weight than those on semaglutide. The average weight loss was 15.2% for tirzepatide users, versus 7.9% for semaglutide users.
The enhanced efficacy of tirzepatide is attributed to its mechanism of action. The drug mimics two gut hormones, GLP-1 and GIP, which influence satiety and blood sugar regulation. Semaglutide, in contrast, mimics only the GLP-1 hormone. This dual-hormone action is believed to contribute to tirzepatide's more potent effects on weight loss.
The study, drawing on real-world data that AgeRejuvenation monitors, underscores the importance of personalized approaches to weight management. While tirzepatide demonstrated superior results, individual responses to medication can vary, necessitating a thorough medical evaluation before initiating treatment.